Top Industry Leaders in the Whole Exome Sequencing Market

-
Sep 2023: In Genome Valley in Hyderabad, Eurofins, a Belgian testing solutions supplier for industries including environment, agrisciences, and life sciences, has launched what is expected to grow to be its largest biopharma services facility in India. The campus, being developed on a 15-acre plot of land, began with a built-up lab area of 1 lakh square feet, but it is anticipated to grow 10X to become a 1 million square foot institution. Global pharmaceutical businesses will receive services from the Eurofins Genome Valley campus in safety toxicology, formulation development, bioanalytical services, and discovery chemistry and biology.
-
Oct 2023: EU antitrust regulators have forced U.S. genetic testing business Illumina to sell cancer test manufacturer Grail after the company closed the purchase before receiving their consent. Fearing that some of these agreements may hinder innovation and diminish competition in the industry, antitrust monitors on both sides of the Atlantic have increased their scrutiny of pharmaceutical and biotech deals in recent years. The EU fined Illumina a record 432 million euros ($457 million) for antitrust violations related to gun-jumping. The $7.1 billion purchase was then banned by the EU competition regulator in 2022 because of worries that Illumina would be motivated to prevent Grail's competitors from using its technology to create their blood-based cancer identification tools.
List of Whole exome sequencing Key companies in the market
- Illumina Inc. (US)
- BGI (China)
- Eurofins Scientific (Belgium)
- Thermo Fisher Scientific (US)
- Agilent Technologies Inc. (US)
- Hoffmann-La Roche Ltd. (Switzerland)
- GENEWIZ (US)
- Ambry Genetics (US)
- Macrogen Inc. (South Korea)
- Integragen SA (France)